Abiogenesis Clinpharm To Conduct Phase III Trial of UTI Drug Phenazopyridine
New Delhi: The Subject Expert Committee (SEC), functional under the Central Drugs Standard Control Organisation (CDSCO), has granted approval to Abiogenesis Clinpharm for conducting the phase III clinical study of Phenazopyridine Hydrochloride 200 mg Tablet.
However, this came with the condition that the firm shall submit the study's Case Report Form (CRF), which includes specific adverse drug reactions during treatment and immediate follow-up of study patients, in addition to any other (new) adverse drug reactions (ADRs).
This took place as the firm presented phase III clinical study Protocol No.: PHN-301-25 Version No. 1.0 dated 06-JUN-2025.
Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms, such as burning and pain during urination.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.